Kelly Chibale

South African Medical Research Council — South Africa

Medicine · Health Sciences

37h-index4.3kcitations176works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Malaria Research and Control(42), Computational Drug Discovery Methods(30), Research on Leishmaniasis Studies(25), HIV/AIDS drug development and treatment(21), Tuberculosis Research and Epidemiology(18)

Publications176 total

Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa
Nature Communications·2025· 2 citedOpen Access
CYP1A2 contributes to the metabolism of mefloquine: Exploration using in vitro metabolism and physiologically-based pharmacokinetic modelling
Drug Metabolism and Disposition·2025Open Access
Chemistry as a Catalyst for Transforming the Health and Wealth of South Africa
Angewandte Chemie International Edition·2025· 2 citedOpen Access
Chemistry as a Catalyst for Transforming the Health and Wealth of South Africa
Angewandte Chemie·2025Open Access
Multi‐target Antimalarials as a Strategy to Reduce Resistance Risk
2024· 3 cited
Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials
Nature Communications·2024· 6 citedOpen Access
AI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa
2024Open Access
Correction: Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Oncogenesis·2024· 2 citedOpen Access
Model‐Informed Approaches to Optimizing Therapeutics in the African Patient Populations
Clinical Pharmacology & Therapeutics·2024· 5 citedOpen Access
Characterization of antimalarial activity of artemisinin-based hybrid drugs
Antimicrobial Agents and Chemotherapy·2024· 3 citedOpen Access
AI can help to tailor drugs for Africa — but Africans should lead the way
Nature·2024· 10 citedOpen Access
Characterization of antimalarial activity of artemisinin-based hybrid drugs
2024Open Access
Drug discovery in Africa tackles zoonotic and related infections
Science Translational Medicine·2023· 1 cited
First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
Nature Communications·2023· 68 citedOpen Access
Developing kinase inhibitors for malaria: an opportunity or liability?
Trends in Parasitology·2023· 13 cited
The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics
Nature Reviews Chemistry·2023· 21 citedOpen Access
Working toward a Globally Diverse and Inclusive Community of Medicinal Chemists of the Future
ACS Medicinal Chemistry Letters·2023· 3 citedOpen Access
Fusidic acid-based drug combinations exhibit enhanced activity against <i>Mycobacterium tuberculosis</i>
2023Open Access
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple <i>Plasmodium</i> kinases and life cycle stages
Science Translational Medicine·2022· 42 citedOpen Access
Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment
Trends in Parasitology·2022· 4 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Gregory S. Smith(8), Janette Reader(6), Lyn‐Marié Birkholtz(6), Elizabeth A. Winzeler(6), Carmen De Kock(6), Sergio Wittlin(5), David A. Fidock(5), Jiří Gut(5), Philip J. Rosenthal(5), Peter J. Smith(5), Sabine Ottilie(5), Manuel Llinás(5), Prinessa Chellan(5), Claire Le Manach(4), Lee M(4), Mariëtte van der Watt(4), Dale Taylor(4), Lauren B. Arendse(4), Digby F. Warner(4), Tanya Paquet(3)